These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 23855420

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Evaluation of dabigatran utilization and risk among hospitalized patients.
    Sidman E, Probst LA, Darko W, Miller CD.
    Ann Pharmacother; 2014 Mar; 48(3):349-53. PubMed ID: 24259660
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry.
    Russo V, Bianchi V, Cavallaro C, Vecchione F, De Vivo S, Santangelo L, Sarubbi B, Calabrò P, Nigro G, D'Onofrio A.
    Eur Rev Med Pharmacol Sci; 2015 Oct; 19(20):3961-7. PubMed ID: 26531286
    [Abstract] [Full Text] [Related]

  • 24. A retrospective descriptive analysis of patient adherence to dabigatran at a large academic medical center.
    Cutler TW, Chuang A, Huynh TD, Witt RG, Branch J, Pon T, White R.
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1028-34. PubMed ID: 25278325
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Direct oral thrombin inhibitor, "dabigatran"].
    Yasaka M.
    Nihon Rinsho; 2013 Jan; 71(1):113-8. PubMed ID: 23631181
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Dabigatran for stroke prevention in atrial fibrillation.
    Hohnloser SH, Diener HC.
    Hamostaseologie; 2012 Jan; 32(3):216-20. PubMed ID: 22739760
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Gorzelak-Pabiś P, Duraj I, Szlagowska L, Ciastkowska A, Broncel M.
    Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J, Delaitre O, Hammès F, de Pouvourville G.
    Arch Cardiovasc Dis; 2014 Nov; 107(6-7):381-90. PubMed ID: 24973113
    [Abstract] [Full Text] [Related]

  • 40. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.
    Ahmad Y, Lip GY.
    Heart; 2012 Oct; 98(19):1404-6. PubMed ID: 22698856
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.